Department of Ophthalmology, University Hospital
Jena, 07743, Germany
NCT Number: NCT00763659
The primary objective of LUTEGA is it to determine the long term effect (about 1 year) of the supplementation with a fixed combination of lutein/zeaxanthin and omega-3- fatty acids on the optical density (OD) of macular pigment in patients with non- exudative age related maculopathy.
Furthermore, it is to be examined whether changes of the optical density are different dosages dependent. Possible changes of lipofuscin content and effect on drusen in AMD patients are studied. The measurement of optical density of macular pigment uses the 1- wavelength reflection method recording reflection images at 460 nm by a fundus camera. The patients are investigated at baseline and are followed up over one year in four more visits. In addition to the OD- measurement each examination includes standardized visual acuity test (ETDRS), amsler- grid, slit lamp biomicroscopy, fundus photography (color and autofluorescence) and a blood sample.
Looking for future studies?
Notify Me50 year–95 year
All sexes
Interventional
Not applicable
Jena, 07743, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
0 mg Lutein, Zeaxanthin, Omega-3-FA
Time frame: 12 months
University of Jena
Other
Acronym: LUTEGA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00494325
Age Related Maculopathy, Eye Diseases
Bern, Switzerland
View Trial DetailsNCT00746668
Age Related Maculopathy, Eye Diseases
Chicago, Illinois, United States
View Trial DetailsNCT01648660
Age Related Maculopathy, Eye Diseases
View Trial DetailsNCT00125632
Age Related Maculopathy, Eye Diseases
Chicago, Illinois, United States
View Trial Details